Centre for Psychiatry South-Wuerttemberg, Weingartshoferstr. 2, 88124, Ravensburg, Germany.
Department Psychiatry I, Ulm University, Ulm, Germany.
CNS Drugs. 2017 Oct;31(10):891-898. doi: 10.1007/s40263-017-0467-3.
The antiepileptic drug pregabalin is one of the best-selling pharmaceutical products worldwide. There are increasing concerns about its potential for misuse and dependence especially among patients with former or current substance use disorders (SUDs).
Our objective was to clarify the extent and pattern of pregabalin use as well as motives and predictors in this population.
We conducted a cross-sectional study with patients on a detoxification ward for illicit drugs at the Center for Psychiatry, Südwürttemberg, Ravensburg in southern Germany from August 2012 until July 2013. We used an extensive questionnaire, part of the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) Axis I Disorders (SCID-I) and urine samples.
Of the 253 participating patients, 56% had used pregabalin at least once. Of these, 92% had acquired it at least in part from illegal sources. The main motives for the use of pregabalin were the attenuation of opioid withdrawal symptoms, the augmentation of other psychotropic substances, and the psychotropic effects of pregabalin itself. Predictors for pregabalin use were opioid and sedative use as well as younger age. The criteria of dependency according to DSM-IV was met by 11% of pregabalin users and 13% of urine samples were positive for pregabalin.
Use of pregabalin is common among users of illicit drugs in large parts of southern Germany, with motives for use, acquisition, and mode of use suggesting misuse. The mode of use, especially intake of high doses and concomitant use of other drugs, poses a serious risk to this population, including the development of dependency.
抗癫痫药物普瑞巴林是全球最畅销的药品之一。人们越来越担心其潜在的滥用和依赖风险，尤其是在有既往或目前物质使用障碍（SUD）的患者中。
我们的目的是阐明该人群中普瑞巴林的使用程度和模式，以及使用的动机和预测因素。
我们在德国南部施瓦本地区拉文斯堡的精神病中心对非法药物戒毒病房的患者进行了一项横断面研究，时间为 2012 年 8 月至 2013 年 7 月。我们使用了一份广泛的问卷，其中一部分是 DSM-IV 轴 I 障碍（SCID-I）的结构性临床访谈和尿液样本。
在 253 名参与研究的患者中，有 56%的患者至少使用过一次普瑞巴林。其中，92%的患者至少部分从非法来源获得普瑞巴林。使用普瑞巴林的主要动机是减轻阿片类药物戒断症状、增强其他精神药物的作用以及普瑞巴林本身的精神作用。普瑞巴林使用的预测因素是阿片类药物和镇静剂的使用以及年龄较小。根据 DSM-IV，11%的普瑞巴林使用者符合依赖标准，13%的尿液样本检测出普瑞巴林阳性。
在德国南部的大部分地区，非法药物使用者中普瑞巴林的使用很常见，使用的动机、获取方式和使用方式表明存在滥用情况。这种使用方式，尤其是高剂量摄入和同时使用其他药物，对这一人群构成了严重风险，包括产生依赖的风险。
